Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Astrazeneca Plc (NY: AZN)
47.68 USD  +0.06 (+0.13%)
Official Closing Price  /  Updated: 6:30 PM EST, Dec 6, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,477,500
Open 47.73
Bid (Size) 47.02 (1)
Ask (Size) 59.92 (1)
Prev. Close 47.62
Today's Range 47.55 - 47.78
52wk Range 35.30 - 49.22
Shares Outstanding 2,533,294,824
Dividend Yield 2.87%
Performance
YTD
+26.14%
+26.14%
1 Month
+0.89%
+0.89%
3 Month
+8.86%
+8.86%
6 Month
+20.43%
+20.43%
1 Year
+24.13%
+24.13%
Top News
More News
CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca today presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that CALQUENCE® (acalabrutinib) combined with obinutuzumab or as monotherapy significantly... Read More
from Business Wire News Releases
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million. Read More
category Stocks / Equities , Pharma/Biotech
from Blogs - TalkMarkets
More News
Read More
Week in Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
from ChinaBio® Today
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
REFILE-AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
AstraZeneca/Merck PARP Inhibitor Approved in China for Ovarian Cancer
from ChinaBio® Today
AstraZeneca-Merck Lynparza wins approval in China for ovarian cancer treatment
category companyNews
from Reuters: Company News
China to use drug bulk-buy program to close price gap
category companyNews
from Reuters: Company News
A Peek Into The Markets: US Stock Futures Signal Lower Start On Wall Street
category Benzinga , TECD , Eurozone , and 11 more.
from Benzinga
Is Clovis Oncology Really a Buyout Candidate?
category CLVS , AZN , JNJ , and 3 more.
from Motley Fool
China Adds 70 Drugs to Insurance Reimbursement List; Negotiates 61% Average Price Cuts
from ChinaBio® Today
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.